Özgür Adıgüzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Özgür Adıgüzel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hümeyra Elif Ateş Eminoğlu
Health Sciences University, Gazi Yaşargil Training and Research Hospital, Turkey
3 shared publications - Süleyman Cemil Oğlak
Department of Obstetrics and Gynecology, Health Sciences University, Gazi Yaşargil Training and Research Hospital
3 shared publications - Abdullah Acar
Health Sciences University, Gazi Yaşargil Training and Research Hospital, Turkey
2 shared publications - Emine Acar
Health Sciences University, Gazi Yaşargil Training and Research Hospital, Turkey
2 shared publications - Fuat Bozan
Health Sciences University, Gazi Yaşargil Training and Research Hospital, Turkey
2 shared publications - Gizem Guzel
Department of Obstetrics and Gynecology, Gazi Yaşargil Training and Research Hospital, Health Sciences University, Diyarbakır, Turkey, sbu.edu.tr
2 shared publications
Latest Publications
- 2 November 2026
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
Diagnostic value of maternal serum prokineticin-1 for predicting placenta accreta spectrum and adverse maternal outcomes
This study aimed to evaluate maternal serum prokineticin-1 (PROK1) levels in women with placenta accreta spectrum (PAS) of varying degrees, to compare them with cases of placenta previa (PP) and uncomplicated healthy pregnancies, and to determine whether this biomarker can predict disease severity and clinical outcomes. In this observational case-control study involving 153 pregnant women, 54 had singleton pregnancies with PP complicated by PAS, 51 had PP without PAS, and 48 were healthy gestational age-matched singleton controls. Demographic and clinical data, maternal and neonatal outcomes, and maternal serum PROK1 levels were collected for all participants. A receiver operating characteristic (ROC) curve was generated to assess the sensitivity and specificity of PROK1, and the optimal cut-off value was determined using the Youden index. Associations between PROK1 levels and continuous clinical variables were analyzed using Spearman’s rank correlation. The mean maternal serum PROK1 level was markedly elevated in both the PAS group (9.29±10.53 pg/mL) and the PP group (6.65±2.88 pg/mL) compared with the control group (3.19±0.81 pg/mL, p<0.001). A cut-off value of 6.81 pg/mL for maternal serum PROK1 distinguished pregnancies complicated by PAS with a sensitivity of 96.3% and a specificity of 97.9%. A statistically significant negative linear correlation was found between maternal serum PROK1 levels and gestational week at delivery (r=–0.598, p<0.001). Additionally, a statistically significant positive correlation was observed between maternal serum PROK1 concentrations and the duration of maternal hospital stay after delivery (r=0.511, p<0.001). Women who required interventions such as transfusion, ICU admission, arterial ligation, uterine resection, or hysterectomy had significantly higher mean PROK1 levels than those who did not. PROK1 is a crucial factor associated with PAS pregnancies, and an increased PROK1 expression in these cases may alter trophoblast function and placentation. The increased PROK1 expression may be considered a potential indicator of disease severity and adverse maternal outcomes.
- 2 November 2026
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
Diagnostic value of maternal serum prokineticin-1 for predicting placenta accreta spectrum and adverse maternal outcomes
This study aimed to evaluate maternal serum prokineticin-1 (PROK1) levels in women with placenta accreta spectrum (PAS) of varying degrees, to compare them with cases of placenta previa (PP) and uncomplicated healthy pregnancies, and to determine whether this biomarker can predict disease severity and clinical outcomes. In this observational case-control study involving 153 pregnant women, 54 had singleton pregnancies with PP complicated by PAS, 51 had PP without PAS, and 48 were healthy gestational age-matched singleton controls. Demographic and clinical data, maternal and neonatal outcomes, and maternal serum PROK1 levels were collected for all participants. A receiver operating characteristic (ROC) curve was generated to assess the sensitivity and specificity of PROK1, and the optimal cut-off value was determined using the Youden index. Associations between PROK1 levels and continuous clinical variables were analyzed using Spearman’s rank correlation. The mean maternal serum PROK1 level was markedly elevated in both the PAS group (9.29±10.53 pg/mL) and the PP group (6.65±2.88 pg/mL) compared with the control group (3.19±0.81 pg/mL, p<0.001). A cut-off value of 6.81 pg/mL for maternal serum PROK1 distinguished pregnancies complicated by PAS with a sensitivity of 96.3% and a specificity of 97.9%. A statistically significant negative linear correlation was found between maternal serum PROK1 levels and gestational week at delivery (r=–0.598, p<0.001). Additionally, a statistically significant positive correlation was observed between maternal serum PROK1 concentrations and the duration of maternal hospital stay after delivery (r=0.511, p<0.001). Women who required interventions such as transfusion, ICU admission, arterial ligation, uterine resection, or hysterectomy had significantly higher mean PROK1 levels than those who did not. PROK1 is a crucial factor associated with PAS pregnancies, and an increased PROK1 expression in these cases may alter trophoblast function and placentation. The increased PROK1 expression may be considered a potential indicator of disease severity and adverse maternal outcomes.
- Open Access
- 17 January 2026
- Published by Wiley in Case Reports in Medicine
- Vol. 2026 (1)
Advanced‐Stage Gonadal Dysgerminoma in a Patient With a Previous Diagnosis of Familial Swyer Syndrome: A Very Rare Genetic Entity
Introduction: Swyer syndrome is a genetic abnormality characterized by a 46,XY karyotype in a phenotypically female individual. Affected individuals typically have average or tall stature, unambiguous genitalia at birth, the presence of Müllerian structures, and bilateral streak gonads. Familial Swyer syndrome is extremely rare, and we identified only two case reports describing families with two and three sisters affected by this syndrome. Individuals with Swyer syndrome have an increased risk of developing gonadal malignancies. Case: A 19‐year‐old patient with primary amenorrhea, who had been followed up with a diagnosis of Swyer syndrome, was referred to our hospital due to a complaint of progressive abdominal distension and a 5‐month history of lower abdominal pain. Karyotype analysis had been performed at another hospital when her older sibling was diagnosed with Swyer syndrome. However, she did not undergo bilateral gonadectomy after the diagnosis was confirmed, as her family postponed the procedure due to the COVID‐19 pandemic. Surgical debulking of ovarian cancer was performed, and histopathology revealed a dysgerminoma, FIGO Stage IIIC. Conclusion: Early diagnosis of Swyer syndrome is essential, considering the significant risk of malignant gonadal tumors that may arise at an early age. Prepubertal female siblings of patients diagnosed with Swyer syndrome should be screened. Early diagnosis and prompt prophylactic gonadectomy can allow for a conservative treatment plan that may preserve fertility and improve patient survival.
- 17 January 2026
- Published by Wiley in Case Reports in Medicine
- Vol. 2026 (1)
Open AccessAdvanced‐Stage Gonadal Dysgerminoma in a Patient With a Previous Diagnosis of Familial Swyer Syndrome: A Very Rare Genetic Entity
Introduction: Swyer syndrome is a genetic abnormality characterized by a 46,XY karyotype in a phenotypically female individual. Affected individuals typically have average or tall stature, unambiguous genitalia at birth, the presence of Müllerian structures, and bilateral streak gonads. Familial Swyer syndrome is extremely rare, and we identified only two case reports describing families with two and three sisters affected by this syndrome. Individuals with Swyer syndrome have an increased risk of developing gonadal malignancies. Case: A 19‐year‐old patient with primary amenorrhea, who had been followed up with a diagnosis of Swyer syndrome, was referred to our hospital due to a complaint of progressive abdominal distension and a 5‐month history of lower abdominal pain. Karyotype analysis had been performed at another hospital when her older sibling was diagnosed with Swyer syndrome. However, she did not undergo bilateral gonadectomy after the diagnosis was confirmed, as her family postponed the procedure due to the COVID‐19 pandemic. Surgical debulking of ovarian cancer was performed, and histopathology revealed a dysgerminoma, FIGO Stage IIIC. Conclusion: Early diagnosis of Swyer syndrome is essential, considering the significant risk of malignant gonadal tumors that may arise at an early age. Prepubertal female siblings of patients diagnosed with Swyer syndrome should be screened. Early diagnosis and prompt prophylactic gonadectomy can allow for a conservative treatment plan that may preserve fertility and improve patient survival.
- Open Access
- 12 February 2025
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-8
The Major Contributors to the Cesarean Section Risk in Nulliparous Women Aged 35 Years and Older
Objective: To assess the association between advanced maternal age (AMA) and cesarean section (CS) risk in nulliparous pregnant women aged 35 years and older and examine potential confounders to enhance guidance for pregnant women and healthcare providers. Study Design: This retrospective cohort study of singleton, nulliparous pregnant women with a fetus in the cephalic presentation admitted for delivery was carried out from 1 January 2022 to 31 December 2022. Maternal demographics, medical history, delivery records, and neonatal outcomes were collected from electronic medical records. Univariate and multiple logistic regression analyses identified variables independently associated with CS in AMA cases. Results: The study included an AMA group (≥35 years, n=52) and a control group (<35 years, n=487). The CS rate was significantly higher in the AMA group (67.3%) compared to the control group (26.1%, p<0.001). Multiple logistic regression revealed that assisted reproductive technology (ART) pregnancies (OR: 39.0), presence of additional maternal disease or pregnancy complication (OR: 5.34), and fetal heart rate (FHR) category III (OR: 3.34) were significantly associated with increased CS risk in AMA women. Conclusion: The risk of CS is significantly elevated in nulliparous women aged 35 and older, particularly among those who conceived through ART, presented with additional maternal diseases, or exhibited FHR category III. These findings provide essential insights for obstetricians to inform AMA patients on CS risks, aiding decision-making.
- 12 February 2025
- Published by Mebas Medikal Basin Yayin Ltd. Sti in Gynecology Obstetrics & Reproductive Medicine
- p. 1-8
Open AccessThe Major Contributors to the Cesarean Section Risk in Nulliparous Women Aged 35 Years and Older
Objective: To assess the association between advanced maternal age (AMA) and cesarean section (CS) risk in nulliparous pregnant women aged 35 years and older and examine potential confounders to enhance guidance for pregnant women and healthcare providers. Study Design: This retrospective cohort study of singleton, nulliparous pregnant women with a fetus in the cephalic presentation admitted for delivery was carried out from 1 January 2022 to 31 December 2022. Maternal demographics, medical history, delivery records, and neonatal outcomes were collected from electronic medical records. Univariate and multiple logistic regression analyses identified variables independently associated with CS in AMA cases. Results: The study included an AMA group (≥35 years, n=52) and a control group (<35 years, n=487). The CS rate was significantly higher in the AMA group (67.3%) compared to the control group (26.1%, p<0.001). Multiple logistic regression revealed that assisted reproductive technology (ART) pregnancies (OR: 39.0), presence of additional maternal disease or pregnancy complication (OR: 5.34), and fetal heart rate (FHR) category III (OR: 3.34) were significantly associated with increased CS risk in AMA women. Conclusion: The risk of CS is significantly elevated in nulliparous women aged 35 and older, particularly among those who conceived through ART, presented with additional maternal diseases, or exhibited FHR category III. These findings provide essential insights for obstetricians to inform AMA patients on CS risks, aiding decision-making.